Leukaemia treatment

The leukaemia service offers rapid diagnosis, immediate inpatient care and a comprehensive outpatient service, with specialist clinics. The service is managed jointly by several clinicians, with specialist interests in different leukaemia subtypes. Close liaison with the bone marrow transplant service is essential for an efficient leukaemia service. Several of the leukaemia clinicians are also involved in providing the BMT service.

Acute myeloid leukaemia and myelodysplasia

A full range of day-case and inpatient treatments is available from simple oral hemotherapy to allogeneic stem cell transplantation. Novel therapies, including phase I/II studies (ie natural killer cell immunotherapy, WT1 vaccination), are an important part of our programme.

Lead clinician – Dr Panos Kottaridis
Clinical nurse specialist – Ms Clara Patmore

Chronic myeloid leukaemia and myelproliferative disorders

A full range of services is provided, from simple oral chemotherapy and targeted therapy to allogenic transplantation in patients with advanced disease.

Lead clinicians – Dr Panos Kottaridis
Lead clinicians – Dr Chris McNamara

Acute lymphoblastic leukaemia

The Royal Free has a long history of leading laboratory-monitoring and clinical practice and in national adult acute lymphoblastic leukaemia studies and trials. The UK adult ALL Minimal Residual Disease laboratory is located here and currently accepts samples from all over the UK for patient-specific Ig/TCR receptor rearrangement analysis. The laboratory is quality assured by participation in a Europewide study group.

Lead clinician – Dr Adele Fielding
Clinical nurse specialist – Ms Clara Patmore

Chronic lymphocytic leukaemia

The Royal Free has a long tradition of clinical practice allied to laboratory research in the field of chronic lymphocytic leukaemia, the commonest leukaemia in western countries. In addition to the routine diagnostic laboratory tests used to detect this disease, we provide a full range of more detailed analysis. These include immunophenotyping of surface antigen markers by flow cytometry, molecular analysis of B-cell receptor status and immunohistochemistry of tissue biopsies, led by Professor Peter Isaacson.

Lead clinician – Dr Archie Prentice